Expertise in
2
conditions

Heather J. Sutherland

Vancouver, BC, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Vancouver, BC, CA 

Overview

Heather Sutherland practices in Vancouver, Canada. Ms. Sutherland is highly rated in 2 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Relapsed Refractory Multiple Myeloma (RRMM), Leukemia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 1 Less Clinical Trial

37 Total Publications

Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.
Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.
Journal: Blood advances
Published: August 18, 2025

Frequently Asked Questions about Heather J. Sutherland

Is Heather J. Sutherland a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Heather J. Sutherland is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Heather J. Sutherland participate in research or clinical trials?

Yes. Heather J. Sutherland has published 37 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Heather J. Sutherland's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sutherland's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile